Opdivo Qvantig™ FDA Approved for Subcutaneous Use in Adult Solid Tumor Indications

Opdivo Qvantig™ FDA Approved for Subcutaneous Use in Adult Solid Tumor Indications Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. This combination…

Read MoreOpdivo Qvantig™ FDA Approved for Subcutaneous Use in Adult Solid Tumor Indications

Takeda Announces HYQVIA® 10% Injection Approval in Japan for Agammaglobulinemia

Takeda Announces HYQVIA® 10% Injection Approval in Japan for Agammaglobulinemia Takeda (TSE:4502/NYSE:TAK) has announced that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the treatment of patients…

Read MoreTakeda Announces HYQVIA® 10% Injection Approval in Japan for Agammaglobulinemia

Wearables to Be Used by 50% of Older Adults for Life-Saving Alerts by 2034, Predicts ScienceSoft

Wearables to Be Used by 50% of Older Adults for Life-Saving Alerts by 2034, Predicts ScienceSoft ScienceSoft has released a comprehensive report examining the future of wearables in preventive healthcare for older adults. The study, supported by data from statistical…

Read MoreWearables to Be Used by 50% of Older Adults for Life-Saving Alerts by 2034, Predicts ScienceSoft

Sensorion Completes Enrollment of First Cohort in Audiogene Phase 1/2 Trial

Sensorion Completes Enrollment of First Cohort in Audiogene Phase 1/2 Trial Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company focused on developing innovative therapies for hearing loss disorders, has successfully completed patient enrollment for the first cohort in its…

Read MoreSensorion Completes Enrollment of First Cohort in Audiogene Phase 1/2 Trial
Anebulo Pharmaceuticals

Anebulo Pharmaceuticals announces positive update and capital raise for Selonabant

Anebulo Pharmaceuticals announces positive update and capital raise for Selonabant Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company focused on developing innovative treatments for acute cannabinoid-induced toxicities, has announced a positive regulatory update and the successful completion of a…

Read MoreAnebulo Pharmaceuticals announces positive update and capital raise for Selonabant